Bladder Cancer Tis
Reviewed by Oncology Team, HealOnco | Last updated: 2026-04
What Tis Means
Carcinoma in situ (CIS). High-grade flat lesion limited to urothelium. Highly aggressive despite superficial appearance. Often multifocal.
Treatment Approach for Tis
TURBT + BCG induction (6 weekly instillations). Maintenance BCG recommended (25% improved recurrence-free survival). Risk of progression 20-30%. Consider cystectomy if BCG-unresponsive.
Survival Rates and Prognosis
The 5-year survival rate for bladder cancer at Tis is approximately 5-year: 60-85% with BCG treatment. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Ta | 5-year: 88-95% | TURBT + intravesical therapy (BCG or mitomycin C). Lifelong surveillance… |
| T1 | 5-year: 70-80% | TURBT + re-TURBT at 3-4 weeks to ensure complete resection and assess response…. |
| T2a | 5-year: 50-60% | Standard: neoadjuvant chemotherapy (gemcitabine-cisplatin or MVAC) followed by… |
| T2b | 5-year: 40-55% | Neoadjuvant gemcitabine-cisplatin (preferred) or MVAC followed by radical… |
| T3a | 5-year: 30-45% | Neoadjuvant chemotherapy (cisplatin-based doublet) mandatory. Radical… |
| T3b | 5-year: 25-35% | Neoadjuvant chemotherapy followed by en bloc resection of involved organs…. |
| T4a | 5-year: 15-25% | Neoadjuvant chemotherapy mandatory but disease likely unresectable. Palliative… |
| T4b | 5-year: <10% | Unresectable disease. Palliative chemotherapy (gemcitabine-cisplatin if fit) or… |
| N0 | Favorable prognostic marker | Enables consideration of bladder-preserving approaches in T1-T2 disease. |
| N1 | 5-year: 35-50% | Neoadjuvant chemotherapy (cisplatin-based) + radical cystectomy with extended… |
| N2 | 5-year: 20-35% | Neoadjuvant chemotherapy essential. Radical cystectomy with extended pelvic and… |
| N3 | 5-year: <15% | Generally unresectable. Neoadjuvant chemotherapy often not tolerated…. |
| M0 | Favorable prognostic marker | Curative intent treatment (cystectomy + chemotherapy) considered. |
| M1a | 5-year: <10% | Palliative chemotherapy (gemcitabine-cisplatin or other platinum-based… |
| M1b | 5-year: <5% | Systemic palliative chemotherapy or immunotherapy. Radiation therapy for… |
Bladder Cancer Treatment in Top Cities
Diagnosed with Tis Bladder Cancer?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free Consultation